Tonix Pharmaceuticals, led by CEO Dr. Seth Lederman, recently announced that their COVID-19 vaccine, TNX-1800, has been chosen for testing in Project Next Gen. This initiative is managed by the White House and the Department of Health and Human Services, NIH, and NIAID.
The TNX-1800 vaccine uses a live virus platform, which provides a unique way of stimulating the immune system. This method offers longer-lasting and potentially transmission-blocking immunity compared to mRNA vaccines. Tonix’s dedication to vaccine development for almost ten years has led to this selection for the program. Moreover, the technology platform can be adapted to protect against other infectious diseases such as monkeypox, smallpox, and tuberculosis.
This choice of TNX-1800 highlights the importance of vaccine platforms in addressing various infectious threats. Tonix’s approach offers the promise of more durable immunity and potential transmission prevention, potentially revolutionizing our approach to infectious disease control. The adaptability of the platform makes it a valuable tool for future vaccine strategies, making it a versatile solution for future pandemics.
For more information about Tonix Pharmaceuticals and their COVID-19 vaccine TNX-1800, please contact Proactive Studio at +1 347-449-0879 or email them at email@example.com.